Tag: Abbott

Abbott partners with NIH on BRAIN initiative to advance research for...

Abbott have announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative...

Burst stimulation of the spinal cord leads to greater pain modulation...

Data from a substudy of SUNBURST suggest that burst stimulation of the spinal cord regulates the medial pain pathway to a greater extent than...

New data show the therapeutic benefits of directional leads for use...

The PROGRESS study has achieved its primary endpoint and demonstrated superiority of the therapeutic window using Abbott directional stimulation compared to omnidirectional stimulation. Results...

Abbott receives CE mark of MR-conditional labelling for Infinity deep brain...

Parkinson’s disease, dystonia and essential tremor patients in CE Mark countries will now benefit from upgraded functionality and new magnetic resonance (MR) conditional labelling...

Positive data for BurstDR spinal cord stimulation

New results from a multicentre study of Abbott’s BurstDR stimulation show that lower-energy, intermittent doses of BurstDR stimulation—known as “microdosing”—can provide pain relief that is...

New approvals allow chronic pain sufferers to try Abbott’s non-opioid pain...

Abbott has announced the launch of the new dorsal root ganglion (DRG) Invisible Trial System, which is approved by the US Food and Drug...

Coverage decision extends DRG therapy to 22 million Americans living with...

Abbott has announced a new national coverage determination for the company's dorsal root ganglion (DRG) neurostimulation pain therapy through Aetna. With this coverage decision,...

Abbott expands its directional deep brain stimulation therapy by offering new...

Parkinson's disease and essential tremor patients can now benefit from upgraded functionality with Abbott's Infinity DBS system. Abbott has announced US Food and Drug...

Evidence in favour of DRG stimulation builds with real-world data

The real-world data collected in the PREDICT study has added to the evidence in favour of dorsal root ganglion (DRG) stimulation for the management...

Spinal cord stimulation reduces or stabilises opioid use among chronic pain...

New research has found spinal cord stimulation therapy can reduce or stabilise the use of opioids in patients battling chronic pain. Researchers examined opioid...

Proclaim DRG Neurostimulation System introduced in Europe

Abbott has announced the European launch of the new Proclaim DRG Neurostimulation System, designed to deliver dorsal root ganglion (DRG) stimulation to patients suffering...

ACCURATE 12-month data published in Pain

New data published in the January edition of Pain has confirmed the superiority of dorsal root ganglion (DRG) stimulation therapy (from Abbott) over traditional...

Abbott completes the acquisition of St Jude Medical

Abbott has now completed the acquisition of St Jude Medical. The Abbott press release announcing the completion of the acquisition said, “The transaction provides...